Advertisement
New Zealand markets close in 5 minutes
  • NZX 50

    11,795.22
    -121.56 (-1.02%)
     
  • NZD/USD

    0.5886
    -0.0020 (-0.34%)
     
  • NZD/EUR

    0.5543
    -0.0011 (-0.20%)
     
  • ALL ORDS

    7,837.70
    -171.70 (-2.14%)
     
  • ASX 200

    7,587.00
    -165.50 (-2.13%)
     
  • OIL

    85.87
    +0.46 (+0.54%)
     
  • GOLD

    2,400.70
    +17.70 (+0.74%)
     
  • NASDAQ

    17,706.83
    -296.65 (-1.65%)
     
  • FTSE

    7,965.53
    -30.05 (-0.38%)
     
  • Dow Jones

    37,735.11
    -248.13 (-0.65%)
     
  • DAX

    18,026.58
    +96.26 (+0.54%)
     
  • Hang Seng

    16,279.56
    -320.90 (-1.93%)
     
  • NIKKEI 225

    38,339.98
    -892.82 (-2.28%)
     
  • NZD/JPY

    90.7820
    -0.2450 (-0.27%)
     

Is Biogen Stock a Buy Now?

Is Biogen Stock a Buy Now?

Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.